Core Laboratories N.V. Logo

Core Laboratories N.V.

CLB

(1.2)
Stock Price

18,59 USD

4.3% ROA

18.74% ROE

44.37x PER

Market Cap.

740.101.824,00 USD

117.56% DER

0.25% Yield

8.03% NPM

Core Laboratories N.V. Stock Analysis

Core Laboratories N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Core Laboratories N.V. Fundamental Stock Analysis
# Analysis Rating
1 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

2 ROE

The stock's ROE falls within an average range (8.73%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (4.3%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (33), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

5 PBV

The stock's elevated P/BV ratio (4.26x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The stock is burdened with a heavy load of debt (118%), making it financially unstable and potentially risky for investors.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Core Laboratories N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Core Laboratories N.V. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Core Laboratories N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Core Laboratories N.V. Revenue
Year Revenue Growth
1995 80.100.000
1996 105.400.000 24%
1997 214.900.000 50.95%
1998 286.200.000 24.91%
1999 303.700.000 5.76%
2000 336.098.000 9.64%
2001 376.572.000 10.75%
2002 364.748.000 -3.24%
2003 405.637.000 10.08%
2004 427.427.000 5.1%
2005 483.467.000 11.59%
2006 575.689.000 16.02%
2007 670.540.000 14.15%
2008 780.836.000 14.13%
2009 695.539.000 -12.26%
2010 794.653.000 12.47%
2011 907.648.000 12.45%
2012 981.080.000 7.48%
2013 1.073.508.000 8.61%
2014 1.085.222.000 1.08%
2015 797.520.000 -36.07%
2016 594.741.000 -34.1%
2017 659.809.000 9.86%
2018 700.846.000 5.86%
2019 668.210.000 -4.88%
2020 487.267.000 -37.13%
2021 470.252.000 -3.62%
2022 489.735.000 3.98%
2023 513.424.000 4.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Core Laboratories N.V. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Core Laboratories N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 15.929.000 100%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 43.185.000 100%
2013 51.988.000 16.93%
2014 45.655.000 -13.87%
2015 49.729.000 8.19%
2016 39.390.000 -26.25%
2017 47.737.000 17.49%
2018 62.910.000 24.12%
2019 48.023.000 -31%
2020 34.033.000 -41.11%
2021 44.173.000 22.96%
2022 38.117.000 -15.89%
2023 65.324.000 41.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Core Laboratories N.V. EBITDA
Year EBITDA Growth
1995 13.100.000
1996 16.900.000 22.49%
1997 37.300.000 54.69%
1998 58.200.000 35.91%
1999 60.400.000 3.64%
2000 52.997.000 -13.97%
2001 70.310.000 24.62%
2002 43.257.000 -62.54%
2003 55.929.000 22.66%
2004 63.150.000 11.43%
2005 84.195.000 25%
2006 136.140.000 38.16%
2007 188.035.000 27.6%
2008 228.486.000 17.7%
2009 211.108.000 -8.23%
2010 250.193.000 15.62%
2011 274.057.000 8.71%
2012 297.280.000 7.81%
2013 333.419.000 10.84%
2014 346.531.000 3.78%
2015 184.013.000 -88.32%
2016 86.179.000 -113.52%
2017 137.380.000 37.27%
2018 141.709.000 3.05%
2019 119.289.000 -18.79%
2020 76.641.000 -55.65%
2021 63.778.000 -20.17%
2022 58.685.000 -8.68%
2023 42.100.000 -39.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Core Laboratories N.V. Gross Profit
Year Gross Profit Growth
1995 15.900.000
1996 20.700.000 23.19%
1997 44.400.000 53.38%
1998 65.700.000 32.42%
1999 58.300.000 -12.69%
2000 67.443.000 13.56%
2001 83.264.000 19%
2002 63.440.000 -31.25%
2003 78.716.000 19.41%
2004 91.035.000 13.53%
2005 115.344.000 21.08%
2006 168.590.000 31.58%
2007 221.349.000 23.84%
2008 266.054.000 16.8%
2009 237.770.000 -11.9%
2010 280.863.000 15.34%
2011 314.279.000 10.63%
2012 336.344.000 6.56%
2013 385.069.000 12.65%
2014 393.255.000 2.08%
2015 237.411.000 -65.64%
2016 125.225.000 -89.59%
2017 160.629.000 22.04%
2018 180.795.000 11.15%
2019 150.026.000 -20.51%
2020 91.633.000 -63.72%
2021 83.840.000 -9.3%
2022 78.919.000 -6.24%
2023 91.136.000 13.41%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Core Laboratories N.V. Net Profit
Year Net Profit Growth
1995 4.200.000
1996 7.700.000 45.45%
1997 15.400.000 50%
1998 20.000.000 23%
1999 3.400.000 -488.24%
2000 19.152.000 82.25%
2001 20.632.000 7.17%
2002 -9.062.000 327.68%
2003 18.700.000 148.46%
2004 12.290.000 -52.16%
2005 31.211.000 60.62%
2006 82.662.000 62.24%
2007 121.105.000 31.74%
2008 143.603.000 15.67%
2009 113.604.000 -26.41%
2010 144.917.000 21.61%
2011 184.684.000 21.53%
2012 216.071.000 14.53%
2013 242.811.000 11.01%
2014 257.485.000 5.7%
2015 114.847.000 -124.2%
2016 63.895.000 -79.74%
2017 83.125.000 23.13%
2018 79.526.000 -4.53%
2019 101.983.000 22.02%
2020 -97.073.000 205.06%
2021 19.727.000 592.08%
2022 19.453.000 -1.41%
2023 9.492.000 -104.94%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Core Laboratories N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 1 0%
2006 2 100%
2007 3 50%
2008 3 0%
2009 2 0%
2010 3 33.33%
2011 4 0%
2012 5 25%
2013 5 20%
2014 6 0%
2015 3 -150%
2016 1 -100%
2017 2 0%
2018 2 0%
2019 2 50%
2020 -2 200%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Core Laboratories N.V. Free Cashflow
Year Free Cashflow Growth
1995 5.400.000
1996 2.500.000 -116%
1997 -17.200.000 114.53%
1998 -20.400.000 15.69%
1999 -14.600.000 -39.73%
2000 -25.578.000 42.92%
2001 -727.000 -3418.29%
2002 21.847.000 103.33%
2003 37.905.000 42.36%
2004 43.308.000 12.48%
2005 55.683.000 22.22%
2006 95.624.000 41.77%
2007 101.551.000 5.84%
2008 123.903.000 18.04%
2009 164.344.000 24.61%
2010 178.030.000 7.69%
2011 173.979.000 -2.33%
2012 204.403.000 14.88%
2013 259.191.000 21.14%
2014 266.009.000 2.56%
2015 194.843.000 -36.52%
2016 120.183.000 -62.12%
2017 105.496.000 -13.92%
2018 90.086.000 -17.11%
2019 67.258.000 -33.94%
2020 45.988.000 -46.25%
2021 23.040.000 -99.6%
2022 14.740.000 -56.31%
2023 -5.377.000 374.13%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Core Laboratories N.V. Operating Cashflow
Year Operating Cashflow Growth
1995 7.700.000
1996 8.800.000 12.5%
1997 -1.900.000 563.16%
1998 6.600.000 128.79%
1999 4.500.000 -46.67%
2000 7.267.000 38.08%
2001 28.318.000 74.34%
2002 40.983.000 30.9%
2003 60.878.000 32.68%
2004 54.196.000 -12.33%
2005 74.778.000 27.52%
2006 120.305.000 37.84%
2007 125.695.000 4.29%
2008 155.207.000 19.01%
2009 181.873.000 14.66%
2010 205.832.000 11.64%
2011 204.126.000 -0.84%
2012 237.202.000 13.94%
2013 298.137.000 20.44%
2014 303.449.000 1.75%
2015 219.100.000 -38.5%
2016 131.887.000 -66.13%
2017 124.271.000 -6.13%
2018 111.827.000 -11.13%
2019 89.527.000 -24.91%
2020 57.868.000 -54.71%
2021 36.579.000 -58.2%
2022 24.956.000 -46.57%
2023 -3.169.000 887.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Core Laboratories N.V. Capital Expenditure
Year Capital Expenditure Growth
1995 2.300.000
1996 6.300.000 63.49%
1997 15.300.000 58.82%
1998 27.000.000 43.33%
1999 19.100.000 -41.36%
2000 32.845.000 41.85%
2001 29.045.000 -13.08%
2002 19.136.000 -51.78%
2003 22.973.000 16.7%
2004 10.888.000 -110.99%
2005 19.095.000 42.98%
2006 24.681.000 22.63%
2007 24.144.000 -2.22%
2008 31.304.000 22.87%
2009 17.529.000 -78.58%
2010 27.802.000 36.95%
2011 30.147.000 7.78%
2012 32.799.000 8.09%
2013 38.946.000 15.78%
2014 37.440.000 -4.02%
2015 24.257.000 -54.35%
2016 11.704.000 -107.25%
2017 18.775.000 37.66%
2018 21.741.000 13.64%
2019 22.269.000 2.37%
2020 11.880.000 -87.45%
2021 13.539.000 12.25%
2022 10.216.000 -32.53%
2023 2.208.000 -362.68%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Core Laboratories N.V. Equity
Year Equity Growth
1995 37.100.000
1996 47.400.000 21.73%
1997 114.100.000 58.46%
1998 197.000.000 42.08%
1999 208.900.000 5.7%
2000 251.858.000 17.06%
2001 275.606.000 8.62%
2002 258.146.000 -6.76%
2003 220.412.000 -17.12%
2004 190.296.000 -15.83%
2005 214.257.000 11.18%
2006 71.836.000 -198.26%
2007 62.143.000 -15.6%
2008 158.153.000 60.71%
2009 279.368.000 43.39%
2010 289.491.000 3.5%
2011 177.903.000 -62.72%
2012 187.913.000 5.33%
2013 169.389.000 -10.94%
2014 93.993.000 -80.21%
2015 -23.699.000 496.61%
2016 155.297.000 115.26%
2017 148.732.000 -4.41%
2018 165.041.000 9.88%
2019 186.415.000 11.47%
2020 79.633.000 -134.09%
2021 165.553.000 51.9%
2022 193.650.000 14.51%
2023 204.916.000 5.5%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Core Laboratories N.V. Assets
Year Assets Growth
1995 65.300.000
1996 79.700.000 18.07%
1997 238.000.000 66.51%
1998 348.600.000 31.73%
1999 361.100.000 3.46%
2000 410.604.000 12.06%
2001 439.500.000 6.57%
2002 421.153.000 -4.36%
2003 421.396.000 0.06%
2004 388.797.000 -8.38%
2005 394.601.000 1.47%
2006 501.215.000 21.27%
2007 504.790.000 0.71%
2008 537.651.000 6.11%
2009 658.166.000 18.31%
2010 636.042.000 -3.48%
2011 605.139.000 -5.11%
2012 636.516.000 4.93%
2013 661.010.000 3.71%
2014 675.653.000 2.17%
2015 625.258.000 -8.06%
2016 573.052.000 -9.11%
2017 584.812.000 2.01%
2018 648.827.000 9.87%
2019 774.673.000 16.25%
2020 568.579.000 -36.25%
2021 580.853.000 2.11%
2022 578.354.000 -0.43%
2023 593.617.000 2.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Core Laboratories N.V. Liabilities
Year Liabilities Growth
1995 28.100.000
1996 32.100.000 12.46%
1997 122.700.000 73.84%
1998 150.500.000 18.47%
1999 150.900.000 0.27%
2000 156.858.000 3.8%
2001 163.079.000 3.81%
2002 162.663.000 -0.26%
2003 199.916.000 18.63%
2004 197.432.000 -1.26%
2005 179.279.000 -10.13%
2006 427.933.000 58.11%
2007 441.161.000 3%
2008 377.340.000 -16.91%
2009 376.408.000 -0.25%
2010 343.702.000 -9.52%
2011 423.484.000 18.84%
2012 448.603.000 5.6%
2013 491.621.000 8.75%
2014 581.660.000 15.48%
2015 648.957.000 10.37%
2016 417.755.000 -55.34%
2017 436.080.000 4.2%
2018 487.927.000 10.63%
2019 592.533.000 17.65%
2020 493.006.000 -20.19%
2021 419.852.000 -17.42%
2022 389.400.000 -7.82%
2023 393.466.000 1.03%

Core Laboratories N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.19
Net Income per Share
0.36
Price to Earning Ratio
44.37x
Price To Sales Ratio
1.94x
POCF Ratio
46.48
PFCF Ratio
82.59
Price to Book Ratio
3.69
EV to Sales
2.51
EV Over EBITDA
19.56
EV to Operating CashFlow
60.35
EV to FreeCashFlow
107.03
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
0,74 Bil.
Enterprise Value
0,96 Bil.
Graham Number
5.87
Graham NetNet
-5.59

Income Statement Metrics

Net Income per Share
0.36
Income Quality
0.95
ROE
0.09
Return On Assets
0.07
Return On Capital Employed
0.11
Net Income per EBT
0.99
EBT Per Ebit
0.76
Ebit per Revenue
0.11
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0.09
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.18
Operating Profit Margin
0.11
Pretax Profit Margin
0.08
Net Profit Margin
0.08

Dividends

Dividend Yield
0
Dividend Yield %
0.25
Payout Ratio
0.08
Dividend Per Share
0.04

Operating Metrics

Operating Cashflow per Share
0.34
Free CashFlow per Share
0.19
Capex to Operating CashFlow
-0.44
Capex to Revenue
-0.02
Capex to Depreciation
-0.56
Return on Invested Capital
0.05
Return on Tangible Assets
0.04
Days Sales Outstanding
105.8
Days Payables Outstanding
44.8
Days of Inventory on Hand
78.64
Receivables Turnover
3.45
Payables Turnover
8.15
Inventory Turnover
4.64
Capex per Share
-0.15

Balance Sheet

Cash per Share
0,35
Book Value per Share
4,29
Tangible Book Value per Share
2
Shareholders Equity per Share
4.29
Interest Debt per Share
5.25
Debt to Equity
1.18
Debt to Assets
0.4
Net Debt to EBITDA
4.47
Current Ratio
2.38
Tangible Asset Value
-0,01 Bil.
Net Current Asset Value
-0,17 Bil.
Invested Capital
1.18
Working Capital
0,13 Bil.
Intangibles to Total Assets
0.35
Average Receivables
0,11 Bil.
Average Payables
0,04 Bil.
Average Inventory
63893500
Debt to Market Cap
0.32

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Core Laboratories N.V. Dividends
Year Dividends Growth
2008 1
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 2 50%
2015 2 0%
2016 2 0%
2017 2 0%
2018 2 -100%
2019 2 50%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Core Laboratories N.V. Profile

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.

CEO
Mr. Lawrence V. Bruno
Employee
3.600
Address
Van Heuven Goedhartlaan 7 B
Amstelveen, 1181 LE

Core Laboratories N.V. Executives & BODs

Core Laboratories N.V. Executives & BODs
# Name Age
1 J. Donald Dumas Jr.
Senior Vice President of Production Enhancement & Business Development
70
2 Ms. Gwendolyn Y. Gresham M.B.A.
Senior Vice President of Corporate Development & Investor Relations
70
3 Mr. Mark Damian Tattoli
Senior Vice President, Secretary & General Counsel
70
4 Mr. Lawrence V. Bruno
Chairman of the Board, Chief Executive Officer, President & Chief Operating Officer
70
5 Mr. Christopher Scott Hill
Senior Vice President & Chief Financial Officer
70
6 Mr. Kevin G. Daniels
Chief Accounting Officer, Treasurer & Vice President
70
7 Mr. Jacobus Schouten
Managing Director
70

Core Laboratories N.V. Competitors